A Dose-Escalation Study of Aerosolized Sargramostim in the Treatment of Metastatic Melanoma
- 1 December 2008
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in American Journal of Clinical Oncology
- Vol. 31 (6), 573-579
- https://doi.org/10.1097/coc.0b013e318173a536
Abstract
Objectives: Early testing of aerosolized sargramostim therapy demonstrated anecdotal clinical responses in patients with metastatic melanoma associated with emergence of systemic antitumor immunity. To improve the clinical and immunologic efficacy of therapy without compromising patient safety, we performed a further dose escalation trial in patients with metastatic melanoma. Methods: We conducted a dose-escalation clinical trial of HLA-A2+ patients with metastatic melanoma to the lung treated with aerosolized granulocyte macrophage colony stimulating factor (GM-CSF) (500–2000 μg/dose, with increments of 250 μg/dose/cohort) twice/d on days 1 to 7 and 15 to 21 every 28 days until progression or severe toxicity to find a dose where a majority of patients develop antitumor immunity. Five patients were treated per each dose level. Clinical, immune, and safety parameters were examined. Results: The study accrued 40 patients. Toxicity was acceptable. All doses levels were exhausted without identifying a dose of GM-CSF at which a majority of patients (≥3 of 5) demonstrated significant up-regulation of antitumor immunity. Three of 16 patients who were tetramer positive for at least one melanoma antigen (eg, MART-1) pretreatment developed an immune response (IR) to different tumor antigens. Two of 9 patients who were tetramer negative to all melanoma antigens pretreatment developed an IR against gp100. The greatest changes in antitumor immunity occurred at the highest dose levels. Conclusions: A dose of aerosolized GM-CSF capable of inducing antitumor immunity in the majority of patients was not reached. All tested doses were well tolerated. The greatest increase in antitumor T cell IRs was achieved at the highest doses of GM-CSF.Keywords
This publication has 26 references indexed in Scilit:
- Nouvelles voies d’administration : vaccinations par voie épidermique, intradermique, muqueusemédecine/sciences, 2007
- Phase I Evaluation of Intranasal Trivalent Inactivated Influenza Vaccine with Nontoxigenic Escherichia coli Enterotoxin and Novel Biovector as Mucosal Adjuvants, Using Adult VolunteersJournal of Virology, 2006
- GM-CSF-secreting melanoma vaccinesOncogene, 2003
- GM‐CSF‐based cancer vaccinesImmunological Reviews, 2002
- Perilesional Injection of r-GM-CSF in Patients with Cutaneous Melanoma MetastasesJournal of Investigative Dermatology, 2001
- Recent Advances in Vaccine Adjuvants for Systemic and Mucosal AdministrationJournal of Pharmacy and Pharmacology, 1998
- Developments in mucosal influenza virus vaccinesVaccine, 1994
- Local and systemic influenza haemagglutinin-specific antibody responses following aerosol and subcutaneous administration of inactivated split influenza vaccineVaccine, 1992
- Immunization Against Measles by AerosolClinical Infectious Diseases, 1983
- CLINICAL TRIAL OF INHALED AEROSOL OF HUMAN DIPLOID AND CHICK EMBRYO MEASLES VACCINESThe Lancet, 1982